The Glabellar Complex · Anatomy and Treatment Logic
What you will find here: 8 in-depth answers on the anatomy of the three glabellar muscles, the mechanism of action at the neuromuscular junction, individual dosing logic, complications and the evidence base. Booking and fee information on the treatment page.
The vertical line between the eyebrows — in technical terms the glabellar complex — is not produced by a single muscle but by the interplay of three. Anyone wanting to understand treatment with botulinum toxin should first look at the anatomy. This page expands on what the treatment page deliberately keeps brief.
The three muscles of the glabellar region
The region between the eyebrows has three important brow depressors — muscles that pull the eyebrow downward when frowning. They lie anatomically close together and work together functionally, but are individually developed to differing degrees. The 2007 consensus recommendations describe this anatomy as follows:
| Muscle | Origin | Insertion | Function |
|---|---|---|---|
| M. corrugator supercilii | Frontal bone, pars nasalis medial to the eyebrow | Galea and skin at the level of the mid-eyebrow | Brow depressor — moves the eyebrow mediocaudally (“frowning”) |
| M. procerus | Nasal bone and upper part of the nasal cartilage | Skin over the root of the nose | Brow depressor and “nose wrinkling” — produces the horizontal line on the bridge of the nose |
| M. depressor supercilii / medialer Anteil M. orbicularis oculi | Skin of the root of the nose | Skin over the medial head of the eyebrow | Brow depressor — moves the eyebrow caudally |
In some people the corrugator is dominant, in others the procerus. In some the depressor supercilii is so weakly developed that it is barely described as a separate muscle anatomically — and indeed not all authors recognise it as an independent muscle. Here the palpating hand sees more than any textbook.
How botulinum toxin acts in the muscle
Botulinum toxin type A is a protein-based active substance that selectively blocks the transmission of the nerve signal at the junction between nerve and muscle — the so-called neuromuscular junction.
The process can be described in four steps:
- Binding. The toxin binds highly selectively to receptors on the presynaptic membrane of the motor nerve ending. It acts only on cholinergic neurons — that is, where acetylcholine serves as the messenger.
- Internalisation. The active substance enters the nerve cell via endocytosis.
- Cleavage of SNAP-25. Inside the cell, the catalytically active domain of the toxin cleaves a specific protein of the SNARE complex — SNAP-25. This protein is essential for the acetylcholine-filled vesicles to fuse with the cell membrane.
- Functional block. Without intact SNAP-25, no acetylcholine can be released into the synaptic cleft. The nerve signal no longer reaches the muscle. The muscle does not contract.
This mechanism is reversible: over the course of weeks the nerve endings form functional sprouts, new SNAP-25 is later produced, and the junction regenerates. Muscle activity returns completely. This is the biological reason for the time-limited effect — and at the same time the most important safety feature of this treatment.
Botulinum toxin does not “paralyse” the muscle in the clinical sense. It reduces its activity for a defined period by interrupting a single molecular transmission step. This is a far more precise process than most patients assume.— Dr. med. Thomas Ackermann · Specialist in Anaesthesiology
Why there is no standard dose
The most common patient question about dosing is: “How many units do I need?” An honest answer is: it depends — on several concrete factors.
The following overview shows the dosing ranges recommended in the literature for botulinum toxin type A in the glabellar region. They make clear how wide the scientific range actually is:
Factors in individual dose selection
- Muscle mass and line depth. Both are palpated and assessed visually at maximum contraction. A strongly developed corrugator muscle requires more active substance than a delicate one.
- Sex. In men the muscle mass in the glabellar region is usually greater and the muscle fibres extend further. Consequence: often additional injection points and 1–2 U more per point.
- Brow position. If the brow sits low on the orbital rim, caution is needed — excessive weakening of the depressors without sufficient residual activity of the frontalis muscle can induce brow ptosis.
- Aesthetic goal. Those who want to pause expression entirely receive a higher dose than those who want to retain residual expression. A so-called mini-dose (9–12 U total) produces a markedly more subtle effect with a cosmetic brow-lift effect.
- Previous treatments. With repeated use the necessary total dose often decreases gradually, because muscle activity is reduced over the long term.
5-point versus 7-point pattern
The 5-point pattern recommended by the summary of product characteristics targets primarily the corrugator and the procerus. With more strongly developed musculature or widely running fibres, additional injection points may be useful — typically 1–2 further points laterally. Which pattern is chosen follows from the individual anatomy, not from a fixed rule.
What is observed — and why most effects are self-limiting
According to the 2007 consensus recommendations, genuine medical complications are very rare. Undesired treatment effects occur in roughly 2–3 % of cases — they are usually mild and time-limited. Importantly: for patients, anything that does not match the desired result counts as a “complication,” even when there is no medical danger. Open, honest counselling is therefore part of the process.
The most common undesired effects — in order of frequency
- Bruising at the injection site. Very fine needles reduce the risk, but small bruises can occur and disappear within 3–7 days.
- Brow asymmetries. At the first treatment of the region, the effect may set in differently on the left and right. At the follow-up appointment this can often be corrected with a minimal touch-up injection.
- Brow ptosis. A slight drop of the eyebrow because the depressors are weakened more than the elevator. Occurs in about 2 %, lasts 3–8 weeks.
- “Mephisto” or “Spock” eyebrow. An unwanted lateral elevation of the eyebrow. Can be corrected with a small additional injection into the lateral frontalis.
- Pseudo eye-bags. Rare after treatment of the lower orbicularis oculi muscle. More of an issue in crow’s feet treatments; barely relevant in pure glabellar treatment.
- Transient headache. 1–2 days. The opposite is in fact more common — in patients with migraine or tension headache, an improvement is often observed.
True eyelid ptosis — rare, but treatable
The rare true ptosis of the upper eyelid arises from diffusion of the active substance toward the levator palpebrae superioris muscle. Frequency: 1–3 % of all glabellar treatments. Duration: 3–8 weeks, fully reversible. It can be treated with alpha-adrenergic eye drops (apraclonidine), which activate the superior tarsal muscle and lift the upper eyelid by a few millimetres — until the toxin effect wears off.
What the treatment is not
Four precise distinctions
- It is not a filler. Botulinum toxin pauses muscle activity — it does not add volume. Very deeply etched static lines of the glabella often additionally require a hyaluronic acid filler. The 2007 consensus recommendations describe the combination of both procedures as “almost mandatory” for deep lines.
- It does not remove the line — it relaxes the muscle that creates it. The skin over the resting muscle smooths passively. With very deeply etched static lines, a residual marking remains because the skin itself is structurally altered (collagen breakdown, loss of elastin).
- It is not “smoothing the forehead.” The glabella (vertical frown line) and horizontal forehead lines are two different indications with different muscle groups — the corrugator complex for the glabella, the frontalis muscle for the forehead. When both are indicated, they are treated together, because an isolated glabellar treatment sometimes leaves an overactivity of the frontalis. But they are planned as methodically separate steps.
- It is not a lift. A subtle medial brow-lift effect arises from weakening the depressors — the elevators (frontalis muscle) gain the upper hand. This effect, however, replaces neither a surgical brow lift nor a HIFU treatment of the forehead-temple region.
What patients want to understand more deeply
Why does the effect only appear after days if the toxin binds immediately?
Binding is rapid — within minutes. The subsequent internalisation and cleavage of SNAP-25, however, takes hours to days. Only once enough SNAP-25 has been broken down in the nerve endings does acetylcholine release fall measurably. Visible muscle weakening typically begins after 2–5 days; full effect is reached after 10–14 days.
How long does the effect last — and why is the range so wide?
The average duration of effect is 4–4.5 months. The range extends from 2.5 months to a maximum of 12 months. It depends on the total dose, the individual speed of nerve regeneration (through sprouting and rebuilding of the SNARE complex), muscle mass, physical activity and genetic factors. With repeated treatments the duration lengthens gradually in many patients, because muscle activity recedes over the long term.
What happens if treatment is continued long-term?
Current long-term studies show no increase in side effects with repeated treatment over many years. A theoretical formation of antibodies against the toxin is discussed in the literature but is rarely clinically relevant. For this reason, touch-up injections are recommended no earlier than 10–14 days after the first treatment, and regular follow-up treatments only after the previous effect has worn off — typically after 3–6 months.
Sind die Wirkstoffe verschiedener Hersteller austauschbar?
No, not 1:1. The approved botulinum toxin type A preparations differ in their unit definitions and are not directly convertible — the unit value of one product can correspond to roughly 2.5 to 3 times the unit of another. Which preparation is used in a specific case depends on practice standards and individual factors — the choice is explained during the consultation.
Are there contraindications?
Yes. Pregnancy and breastfeeding, neuromuscular disorders such as myasthenia gravis, acute infections in the treatment area, known allergies to components of the preparation. When certain medications are being taken (aminoglycoside antibiotics, muscle relaxants), treatment is usually postponed or the dose adjusted. A careful medical history is taken before the first appointment.
What happens to facial expression — do I still look natural afterwards?
This is the design question of the treatment. A dose that is too strong can noticeably pause expression — a “frozen” face. A well-measured treatment reduces the unwanted muscle activity (the automatic frowning during concentration) while preserving expression in conversation. The goal is not “no lines” — the goal is that the glabella is no longer permanently tense when you are relaxed.
What about migraine or bruxism — are those different treatments?
Yes. Chronic migraine and nocturnal teeth grinding (bruxism) are independent medical indications that are also treated with botulinum toxin — but at other muscle groups (the PREEMPT protocol for migraine, the masseter for bruxism). If someone wants migraine treatment and a glabellar treatment at the same time, the indications can often be carried out in the same appointment, but must be planned as methodically separate steps.
Who should rather not have this treatment?
Patients who expect an immediate, drastic change — the effect builds over days, and the final result is a subtle change in muscle activity, not a complete smoothing of lines. Patients who frequently check the mirror and are easily unsettled also often benefit more from thorough counselling before the first appointment than from the treatment itself.
The scientific basis for the treatment
Glabellar treatment with botulinum toxin type A is among the best-studied indications in all of aesthetic medicine. It was first described in 1992 and has been approved for this indication in Germany under medicines law since January 2006.
Carruthers JD & Carruthers JA, 1992 — Erstbeschreibung der Indikation
Treatment of glabellar frown lines with C. botulinum-A exotoxin. Journal of Dermatologic Surgery and Oncology, 18 (1): 17–21. The Carruthers (a physician couple from Vancouver) incidentally observed, while treating blepharospasm with botulinum toxin, the smoothing side effect on the glabellar region — and from this described the first aesthetic indication. This publication is regarded as the birth of aesthetic botulinum toxin therapy.
Sommer B, Bergfeld D, Sattler G (Hrsg.), 2007 — Deutschsprachiger Konsensus
Konsensusempfehlungen zum Gebrauch von Botulinumtoxin A in der ästhetischen Medizin. JDDG · Journal of the German Society of Dermatology, Supplement 1, Band 5. By far the most important German-language consensus on the practical conduct of the treatment. For each treatment region it describes the target musculature, dosing ranges, injection patterns, complication patterns and management pathways for undesired effects. Most of the practical statements on this page draw on this consensus.
Cotofana S & de Maio M, 2018 — Anatomische Zonen-Map
Botulinum toxin injection patterns for the upper face. A detailed anatomical zone map for the forehead (frontalis muscle, 12 zones) and glabella, with individualised dosing recommendations depending on muscle course and brow position. An important refinement of the older patterns toward more precise topography.
Wiest L et al. — Lehrbuch Praktische Durchführung
Faltenbehandlung mit Botulinumtoxin A und besondere Indikationen. Springer-Lehrbuch. A standard reference on the practical conduct of the treatment, with a detailed description of injection technique, complication management and patient guidance. Among other things, it describes the rare presentations such as the “Spock sign” and “Mephisto eyebrow” with concrete correction pathways.
This selection represents the essential sources of this collection — it is not exhaustive. For the glabellar indication in particular, numerous randomised controlled trials exist on dose-finding, duration of effect and safety. The works cited here form the methodological framework for everyday clinical decisions.
Would you like to discuss the treatment in person?
The treatment page with the treatment process, duration of effect and fee information is here:
Frown lines · Treatment overviewFor an overview of all wrinkle treatments with botulinum toxin type A, see the category page.
For patients from the Erlangen area: botulinum toxin near Erlangen.
Dr. med. Thomas Ackermann
Specialist in Anaesthesiology · Medical Director, Harmonie der Ästhetik
The background in anaesthesiology shapes the approach to botulinum toxin treatments — the precise control of dose- and time-dependent agents is daily practice in anaesthesia. This page was last reviewed on 17 May 2026.
Skin Analysis
Wrinkles & Muscle Relaxants
Bio-Regeneration (Skin Quality)
HIFU Lifting
Primary Care Support
Tension & Pain
Hair Health & Hair Loss
Skin Diseases
Drip Spa & Infusion Medicine
